Literature DB >> 10501478

Sexual dimorphism in the response to N-methyl-D-aspartate receptor antagonists and morphine on behavior and c-Fos induction in the rat brain.

D N D'Souza1, R E Harlan, M M Garcia.   

Abstract

It has been suggested that there are sex differences in the neural response to drugs of abuse. Previous studies have shown that, upon administration of morphine, the immediate early gene c-Fos is induced in the striatum, nucleus accumbens and cortex of the rat brain. This induction of c-Fos is reduced by administration of the N-methyl-D-aspartate receptor antagonist dizocilpine maleate. However, in studies using immunocytochemistry, we found that the pattern of this expression differed markedly between the sexes. In male rats treated with morphine (10 mg/kg, s.c.) and killed 2 h later, there was an induction of c-Fos in the dorsomedial caudate-putamen, the nucleus accumbens and in the intralaminar nuclei of the thalamus. Administration of dizocilpine maleate (0.2 mg/kg, i.p.; 30 min before morphine) partially blocked the response in the caudate-putamen, but not in the thalamus. In females, morphine induced c-Fos in the caudate-putamen, but with more inter-animal variability than in males. In the midline intralaminar thalamic nuclei, female rats showed less induction than males. In male rats, dizocilpine maleate alone caused negligible induction of c-Fos, whereas in female rats, it caused a large induction in the rhomboid, reuniens and central medial nuclei of the thalamus, and in the cortex. Whereas dizocilpine maleate partially blocked the morphine-induced c-Fos expression in the caudate-putamen of males, it completely blocked this response in females. With dizocilpine maleate alone, there was little or no effect on behavior in male rats, whereas in female rats, it caused head bobbing, thrashing, hyperactivity and uncoordinated movements. These behavioral sex differences were not seen on treatment of rats with the competitive N-methyl-D-aspartate receptor antagonist 2R,4R,5S-2-amino-4,5-(1,2-cyclohexyl)-7-phosphoheptanoic acid (NPC-17742; 10 mg/kg, i.p.) and this drug did not induce c-Fos expression in either sex. In the caudate-putamen, morphine-induced c-Fos expression was significantly reduced by NPC-17742 (30 min before morphine) in males and completely blocked in females. These results suggest that the responses to both morphine and N-methyl-D-aspartate receptor antagonists differ between the sexes and emphasize that glutamate is involved in morphine-induced immediate early gene expression in the brain. These studies thus have important implications for gender differences in drug addiction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501478     DOI: 10.1016/s0306-4522(99)00229-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Greater vulnerability to the amnestic effects of ketamine in males.

Authors:  Celia J A Morgan; Edward B Perry; Hyung-Sang Cho; John H Krystal; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

2.  Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum.

Authors:  Anthony H Stonehouse; Frederick S Jones
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Gabapentin completely attenuated the acute morphine induced c-Fos expression in the rat striatum.

Authors:  Jamil Ahsan Kazi; Chen Fun Gee
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

4.  mu-opioid receptor-mediated antinociceptive responses differ in men and women.

Authors:  Jon-Kar Zubieta; Yolanda R Smith; Joshua A Bueller; Yanjun Xu; Michael R Kilbourn; Douglas M Jewett; Charles R Meyer; Robert A Koeppe; Christian S Stohler
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

Review 5.  Rostral Intralaminar Thalamus Engagement in Cognition and Behavior.

Authors:  Kara K Cover; Brian N Mathur
Journal:  Front Behav Neurosci       Date:  2021-04-15       Impact factor: 3.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.